
Novartis forecasts 5% sales growth CAGR through 2031 with upgraded peak sales for key drugs.
Novartis projects a 5% compound annual growth rate (CAGR) in net sales from 2026 to 2031 and aims to restore its core operating income margin to over 40% by 2029. The company raised peak sales forecasts for key drugs Kesimpta, Scemblix, and Leqvio, r...





